Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

In this analysis (BMJ 2020;369:m1107, doi:10.1136/bmj.m1107, published 29 April 2020), one of the five serious risks of SGLT2 inhibitors was omitted—acute kidney injury. The full list is diabetic…


Read Original Article: Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators »